Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

BACKGROUND: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes. The objective of this study was to investigate the impact of CYP2D6 polymorphisms on...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennig, Ewa E., Piatkowska, Magdalena, Karczmarski, Jakub, Goryca, Krzysztof, Brewczynska, Elzbieta, Jazwiec, Radoslaw, Kluska, Anna, Omiotek, Robert, Paziewska, Agnieszka, Dadlez, Michal, Ostrowski, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522133/
https://www.ncbi.nlm.nih.gov/pubmed/26232141
http://dx.doi.org/10.1186/s12885-015-1575-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522133/
https://www.ncbi.nlm.nih.gov/pubmed/26232141
http://dx.doi.org/10.1186/s12885-015-1575-4

Ejemplares similares